Effects Of Curcuminoids Plus Piperine On Glycemic, Hepatic And Inflammatory Biomarkers In Patients With Type 2 Diabetes Mellitus: A Randomized Double-Blind Placebo-Controlled Trial
Notes for this study:
||HOMA-IR. Placebo: before 3.2 ± 0.5, after 3.1 ± 0.4. Curcumin: before 8.1 ± 2.1, after 7.4 ± 2.0
|Number of Subjects
||18-29, 30-44, 45-64, 65+
||Obese, Overweight, Average, Underweight
In a randomized, double-blind, placebo-controlled trial, 118 participants with type 2 diabetes were assigned to take either placebo or 500 mg of curcuminoids with 5 mg of piperine daily for 3 months.
Funding issues for this study:
25% of participants failed to complete the trial. Compared with the placebo group, the curcumin group saw a statistically significant reduction in weight/BMI, fasting glucose, HbA1c, c-peptide, ALT, and AST. There was no statistically significant difference for insulin, hd-CRP, creatinine, HOMA-IR, HOMA-B, or hepatic steatotic index.
When grouped by gender, males had a statistically significant decrease in glucose but not females, and females had a statistically significant decrease in HbA1c and AST but not males.
Conflict of interest: "Muhammed Majeed is the Founder & Chairman of Sabinsa Corporation
and Sami Labs Limited."